GlassScriptPhysician profile
Richard A Beham
NPI 1568468023
$2,215.64
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,964 · 2020: $252.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $252.95 | 2019 | |
| Lilly USA, LLC | $167.06 | 2019-2020 | |
| Medtronic Minimed, INC. | $164.85 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $162.29 | 2019-2020 | |
| Dexcom, INC. | $159.66 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $137.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $137.49 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $103.55 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.51 | 2019 | |
| Amgen INC. | $91.97 | 2019 | |
| Abbott Laboratories | $76.51 | 2019-2020 | |
| Radius Health, INC. | $63.83 | 2019 | |
| Becton, Dickinson and Company | $63.28 | 2019-2020 | |
| Abbvie INC. | $61.16 | 2019 | |
| Mannkind Corporation | $56.53 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $51.37 | 2019 | |
| Insulet Corporation | $50.99 | 2019 | |
| Merck Sharp & Dohme LLC | $46.67 | 2019 | |
| Shire North American Group INC | $46.50 | 2019 | |
| Amarin Pharma, INC. | $39.95 | 2019 | |
| Pfizer INC. | $35.25 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.57 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.65 | 2019 | |
| Antares Pharma, INC. | $15.88 | 2019 | |
| Lifescan, INC. | $15.78 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.01 | 2019 | |
| Horizon Therapeutics Plc | $12.99 | 2020 | |
| Gilead Sciences, INC. | $11.72 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Beham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.